Table 12 Characteristics of included studies- renal cancer
From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
|---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Karami S [203], 2016, US | M/F | 2002–2007 | US Kidney Cancer Study | 1187 | 1204 | Renal-cell cancer | Questionnaires | Use at least once a week for 3 months or longer, at least 2 years prior to the interview | 1,2,3,4,5,10,11, 27,51,52 | 8 |
Tavani A [204], 2010, Italy | M/F | 1992–2004 | Population from Italian areas | 755 | 1297 | Renal-cell cancer | Questionnaires | Use at least once a week for more than 6 months(regular) | 1,2,3,5,6,7,27,55,56 | 7 |
Gago-Dominguez M [205], 1999, US | M/F | 1986–1994 | Patients from Los Angeles County | 1204 | 1204 | Renal-cell cancer | Questionnaires | Had ever taken the drug 20 or more times | 3,5,10,27,57 | 6 |
Chow WH [206], 1994, US | M/F | 1988–1990 | Population from Minnesota | 440 | 691 | Renal-cell cancer | Interviewer | Use at least 2 or more times per week for 1 month or longer (regular) | 1,3,10 | 6 |
McCredie M [207], 1993, Austrilia | M/F | 1989–1990 | The NSW Central Cancer Registry | 489 | 523 | Renal-cell cancer | Questionnaires | Had ever taken the drug 20 or more times | 1,2,3,50,58, | 7 |
McCredie M [208], 1988, Austrilia | M/F | 1977–1982 | New South Wales Central Cancer Registry | 360 | 985 | Kidney cancer | Questionnaires | Had taken a total of more than 0.1 kg | 1,2,3,44,59,60,61 | 6 |
Cohort studies | ||||||||||
Karami S [203], 2016, US | M/F | 2002–2007 | Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial | 135 | 98,807 | Renal cell carcinoma | Questionnaires | Use at least once per week | 1,3,5,10,11,27,51 | 7 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 329 | 141,880 | Kidney cancer | Questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6,10,11,17,18,19,25,26,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Liu W [209], 2013, US | M/F | 1996–2006 | AARP | 884 | 298,468 | Renal cell carcinoma | Questionnaires | Any use of aspirin | 1,2,3,4,5,6,7,10,11,18,27,53,54 | 7 |
Cho E [210], 2011, US | F | 1986–2006 | NHS | 153 | 77,525 | Renal cell carcinoma | Questionnaires | Use aspirin ≥2 times/week(regular) | 1,3,6,10,18,19,27,39 | 7 |
M | 1990–2006 | HPFS | 180 | 49,403 | Renal cell carcinoma | Questionnaires | Use aspirin ≥2 times/week(regular) | 1,3,6,10,18,19,27 | 9 | |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 365 | 146,113 | Kidney cancer | Questionnaires | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,20,25, 27,45 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 67 | 29,470 | Kidney cancer | Prescription database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 32 | 12,668 | Kidney cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |
Paganini-Hill A [103], 1989, US | M/F | 1981–1988 | Population from Leisure World, Laguna Hills, US | 25 | 13,870 | Kidney cancer | Questionnaires | Aspirin use: none,<daily, daily | 2 | 4 |